Forecast Report - Epilepsy Therapeutics Market Size, Share, Growth & Worldwide, 2019: Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. Read Complete Report with TOC @ http://www.radiantinsights.com/research/epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic Scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries. Scope The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes - - A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options - In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters - A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability
The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic Scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -
- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Figure 6: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Vimpat, Global, Revenue ($m), 2009-2013 20<br />
Figure 7: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Global, Comparative Safety and Efficacy of <strong>Market</strong>ed Products (Heat<br />
Map), 2013 24<br />
Figure 8: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Global, Overall Pipeline Analysis, 2013 27<br />
Figure 9: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Global, Pipeline Analysis, by Mechanism of Action, 2013 28<br />
Figure 10: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Global, Clinical Trial Failure Rate, 2013 30<br />
Figure 11: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Global, Pipeline, Clinical Trial <strong>Size</strong>, 2013 31<br />
Figure 12: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Global, Pipeline, Clinical Trial Duration, 2013 32<br />
Figure 13: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Asia-Pacific, <strong>Market</strong> <strong>Size</strong>, 2012-<strong>2019</strong> 35<br />
Figure 14: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, China, <strong>Market</strong> <strong>Size</strong>, 2012-<strong>2019</strong> 37<br />
Figure 15: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, India, <strong>Market</strong> <strong>Size</strong>, 2012-<strong>2019</strong> 39<br />
Figure 16: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Japan, <strong>Market</strong> <strong>Size</strong>, 2012-<strong>2019</strong> 41<br />
Figure 17: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Australia, <strong>Market</strong> <strong>Size</strong>, 2012-<strong>2019</strong> 43<br />
Figure 18: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Deals by Region, Value and Year, 2006-2013 45<br />
Figure 19: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Deals by Molecule Type and Mechanism of Action, 2006-2013 46<br />
Figure 20: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Co-development Deals, Territory, 2006-2013 47<br />
Figure 21: <strong>Epilepsy</strong> <strong>Therapeutics</strong>, Licensing Deals, by Territory, 2006-2013 48<br />
Figure 22: GBI Research <strong>Market</strong> <strong>Forecast</strong>ing Model 65<br />
Latest <strong>Report</strong> by <strong>Radiant</strong> <strong>Insights</strong><br />
<strong>Epilepsy</strong> <strong>Therapeutics</strong> in Major Developed <strong>Market</strong>s to <strong>2019</strong> -<br />
http://www.radiantinsights.com/research/epilepsy-therapeutics-in-major-developed-markets-to-<br />
<strong>2019</strong>-new-aeds-with-novel-mechanisms-of-action-signal-a-shift-in-treatment-patterns<br />
Summary<br />
GBI Research has released its pharma research, "<strong>Epilepsy</strong> <strong>Therapeutics</strong> in Major Developed <strong>Market</strong>s to<br />
<strong>2019</strong> - New AEDs with Novel Mechanisms of Action Signal a Shift in Treatment Patterns", which<br />
provides in-depth analysis of epilepsy market within the eight major developed markets of the US, UK,<br />
France, Germany, Italy, Spain, Japan and Canada. The report provides an estimation of the market size<br />
for 2012, along with market forecasts to <strong>2019</strong>. It also covers disease epidemiology, treatment algorithms,<br />
treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Change language